Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 16 | ECE2008 | Next issue

10th European Congress of Endocrinology


Clinical highlights

ea0016s30.1 | Clinical highlights | ECE2008

Reversible Kallmann syndrome associated with a novel homozygous mutation in the prokineticin receptor-2 gene

Asci Roberta , Bellastella Giuseppe , Maione Luigi , Quinto Maria Chiara , De Bellis Annamaria , Jolascon Achille , Bellastella Antonio , Agostino Sinisi Antonio

Reversible Kallmann syndrome (KS) is a rare variant of hypogonadotropic hypogonadism (HH) reported in men, in which gonadotropin, testosterone (T) and fertility recover spontaneously following treatment with gonadotropins or T. In a few cases mutations of FGFR1 and KAL1 genes have been found. In this report we describe a subject with a KS carrying a new homozygous mutation of PROK-R2 gene and displaying an apparent reversal of his reproductive condition. The proband, born from...

ea0016s30.2 | Clinical highlights | ECE2008

Contrast-enhanced ultrasound of adrenal mass: differentiation between benign and malignant lesions

Friedrich-Rust Mireen , Schneider Guenther , Bohle Rainer M , Zeuzem Stefan , Bojunga Jorg

Background: Adrenal masses can be detected by ultrasound with high sensitivity and specificity. However, a differentiation between benign and malignant adrenal masses is presently not possible. Contrast-enhanced ultrasound has been studied intensively with excellent results for the characterization of liver lesions.The aim of the present study was to evaluate the value of contrast-enhanced ultrasound for the characterization of adrenal mass in a proof of...

ea0016s30.3 | Clinical highlights | ECE2008

[123I]Iodometomidate as a radiotracer for diagnosis of adrenal tumours and adrenocortical carcinoma

Hahner Stefanie , Schirbel Andreas , Kreissl Michael , Fassnacht Martin , Johanssen Sarah , Beuschlein Felix , Quinkler Marcus , Reincke Martin , Stuermer Andrea , Reiners Christoph , Allolio Bruno

Subject: Adrenal tumours (AT) are often detected incidentally and represent a variety of differential diagnoses with variable therapeutic consequences. We have recently developed [123I]Iodometomidate ([123I]IMTO), that specifically binds to adrenal CYP11B enzymes as a SPECT tracer for adrenal scintigraphy. This radiotracer is now evaluated in patients with adrenal tumours in an ongoing clinical trial. The study was approved by the ethical committee and pa...

ea0016s30.4 | Clinical highlights | ECE2008

Evaluation of endothelial function and endothelial nitric oxide synthase intron 4a/b polymorphism in primary hyperparathyroidism

Ekmekci Ahmet , Abaci Neslihan , Agayev Ayaz , Aksakal Nihat , Oflaz Huseyin , Unaltuna Nihan Erginel , Erbil Yesim , Ozbey Nese Colak

The aim of this study is to evaluate endothelial function in patients with primary hyperparathyroidism (pHT) during the preoperative hypercalcemic and postoperative normocalcemic periods and to determine whether intron 4a/b polymorphism of eNOS gene influences endothelial function. Forty-one patients with pHT (28 women, 12 men; age: 48.4±11.6 years, serum calcium: 11.4±1.0 mg/dl, parathyroid hormone: 373.3±394.5 pg/ml) who fulfilled the criteria for parathyroid ...

ea0016s30.5 | Clinical highlights | ECE2008

Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline: dose and treatment duration effect

Colao Annamaria , Galderisi Maurizio , Sarno Antonella Di , Pardo Moira , Gaccione Maria , D'Andrea Marianna , Pivonello Rosario , Guerra Ermelinda , Lerro Giuseppe , Lombardi Gaetano

Background: Cabergoline, a dopamine receptor-2 agonist, used to treat prolactinomas was associated with increased risk of cardiac valve disease.Objective: To evaluate prevalence of cardiac valve regurgitation in patients with prolactinomas treated with cabergoline.Design: Open, case–control, prospective.Patients: Fifty patients (44 women, 6 men) and 50 sex- and age-matched control subjects.<p class="...

ea0016s30.6 | Clinical highlights | ECE2008

Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial

Glintborg Dorte , Andersen Marianne , Hagen Claus , Heickendorff Lene , Hermann Anne Pernille

Background: PPARγ-agonist treatment may decrease bone mineral density (BMD) in postmenopausal women. The hypothesis that premenopausal women are relatively protected from mineral loss during PPARγ-agonist treatment has not been evaluated in clinical studies.Aim: To investigate the effect of pioglitazone on BMD and bone turnover markers in patients with polycystic ovary syndrome (PCOS).Methods: Thirty premenopausal PCOS pa...